Tous Actualités
Suivre
Abonner Helsinn Healthcare SA

Helsinn Healthcare SA

Helsinn announces completion of its new Stability Centre at its Irish drug product manufacturing facility

Dublin, Ireland (ots)

Helsinn announces the completion of its
state of the art Stability Centre at its Helsinn Birex 
Pharmaceuticals facility in, Dublin, Ireland.
The new facility which has a total storage capacity of 24 cu 
meters, contains a range of stability chambers which will operate at 
ICH conditions of 25°C/60% RH, 30°C/65% RH, and 40°C/75% RH. It also 
has a refrigerated chamber to store samples at 5°C and a freezer at 
minus 20°C.
The centre has the capacity to meet foreseeable stability 
requirements of the Helsinn Group for commercial and development 
products currently in the Helsinn pipeline. It is also available as a
service for third party clients.
The centre possesses state of the art monitoring and recording 
systems for Security and operational performance, and for emergency 
back up in the case of power failure or other unforeseen events.
"The completion of this new stability center at Helsinn Birex 
Pharmaceuticals provides an important addition to Helsinn's 
capability to monitor the quality of its product portfolio as part of
its commitment to excellent service to its customers worldwide", says
Padraig Somers, General Manager. "Additionally, it complements 
Helsinn's capabilities to optimize its product formulations during 
the development process".
About Helsinn Group
Helsinn is a privately owned pharmaceutical group with 
headquarters in Lugano, Switzerland, and subsidiaries in USA and 
Ireland. Helsinn's unique business model is focused on the licensing 
of pharmaceuticals and medical devices in therapeutic niche areas. 
The Group in-licenses early stage new chemical entities, completes 
their development from the performance of pre-clinical/clinical 
studies and Chemistry, Manufacturing and Control (CMC) development, 
to the filing for and attainment of their market approval worldwide.
Helsinn's products are sold directly, through the Group 
subsidiaries, or eventually out-licensed to its network of local 
marketing and commercial partners, selected for their deep in-market 
knowledge and know-how, and assisted and supported with a full range 
of product and scientific management services, including commercial, 
regulatory, financial, legal and medical marketing advice.
The active pharmaceutical ingredients and the finished dosage 
forms are manufactured at Helsinn's cGMP facilities in Switzerland 
and Ireland, and supplied worldwide to its customers. Helsinn is the 
worldwide licensor of palonosetron, a second generation 5-HT3 
receptor antagonist, for the prevention of chemotherapy-induced 
nausea and vomiting (CINV) and of post-operative nausea and vomiting 
(PONV) in patients with cancer, and of the original nimesulide, a 
non-steroidal anti-inflammatory drug (NSAID) distributed in more than
50 countries worldwide. Helsinn, with a workforce of around 450 
employees in Switzerland, Ireland and USA, reported a 2008 turnover 
of over CHF 280.3 million (about EUR 178 million), covering 75 
countries worldwide, with over 20% of this turnover invested in R&D.
For more information about Helsinn Group, please visit the 
website: www.helsinn.com

Contact:

Helsinn Healthcare SA
Paola Bonvicini
Head of Communication & Press Office
Tel: +41/91/985'21'21
E-Mail: info-hhc@helsinn.com

Plus de actualités: Helsinn Healthcare SA
Plus de actualités: Helsinn Healthcare SA